ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.6724
-0.0296 (-4.22%)
At close: Jun 6, 2025, 4:00 PM
0.6750
+0.0026 (0.39%)
After-hours: Jun 6, 2025, 6:41 PM EDT
ImmunoPrecise Antibodies Revenue
ImmunoPrecise Antibodies had revenue of 6.15M CAD in the quarter ending January 31, 2025, a decrease of -1.13%. This brings the company's revenue in the last twelve months to 24.00M, up 1.34% year-over-year. In the fiscal year ending April 30, 2024, ImmunoPrecise Antibodies had annual revenue of 24.52M with 18.65% growth.
Revenue (ttm)
24.00M CAD
Revenue Growth
+1.34%
P/S Ratio
1.21
Revenue / Employee
237,604 CAD
Employees
101
Market Cap
30.77M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2024 | 24.52M | 3.85M | 18.65% |
Apr 30, 2023 | 20.67M | 1.30M | 6.72% |
Apr 30, 2022 | 19.36M | 1.45M | 8.11% |
Apr 30, 2021 | 17.91M | 3.85M | 27.42% |
Apr 30, 2020 | 14.06M | 3.13M | 28.66% |
Apr 30, 2019 | Pro | Pro | Pro |
Apr 30, 2018 | Pro | Pro | Pro |
Apr 30, 2017 | Pro | Pro | Pro |
Apr 30, 2016 | Pro | Pro | Pro |
Apr 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IPA News
- 1 day ago - ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery - Business Wire
- 16 days ago - ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts - Business Wire
- 17 days ago - ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference - Business Wire
- 25 days ago - IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - Business Wire
- 2 months ago - ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods - Business Wire
- 2 months ago - ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 - Business Wire
- 3 months ago - ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. - Business Wire